BioCentury | Feb 7, 2018
Distillery Therapeutics

Cancer

...and in Phase I testing for non-Hodgkin’s lymphoma (NHL). Idera Pharmaceuticals Inc. has TLR9 agonist EMD 1201081...
BioCentury | May 21, 2012
Clinical News

IMO-2055: Phase Ib data

...IMO-2055 was identified as the recommended Phase II dose. Last year, Idera regained rights to IMO-2055...
...& Dec. 5, 2011). Idera plans to make a decision regarding next steps for the IMO-2055...
...the 3 companies market the drug. Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Cambridge, Mass. Product: IMO-2055 , EMD 1201081...
BioCentury | May 7, 2012
Finance

Highlights of weekly biotech stock moves

...Story) . Idera Pharmaceuticals Inc. (NASDAQ:IDRA) was off $0.36 (25%) to $1.10 last week after IMO-2055...
...NYSE:LLY), Bristol-Myers Squibb Co. (NYSE:BMY) and Merck KGaA (Xetra:MRK) market Erbitux. Merck returned rights to IMO-2055...
BioCentury | May 7, 2012
Clinical News

IMO-2055: Phase II data

...or metastatic SCCHN who were naïve to Erbitux cetuximab showed that once-weekly subcutaneous 0.32 mg/kg IMO-2055...
...IMO-2055 plus Erbitux vs. 1.9 months for Erbitux alone. Last year, Idera regained rights to IMO-2055...
...U.S., while Roche markets it elsewhere. Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Cambridge, Mass. Product: IMO-2055 , EMD 1201081...
BioCentury | May 4, 2012
Clinical News

Idera's IMO-2055 misses SCCHN endpoint

...Idera Pharmaceuticals Inc. (NASDAQ:IDRA) said once-weekly subcutaneous IMO-2055 plus Erbitux cetuximab missed the primary endpoint of...
...metastatic SCCHN who were naive to Erbitux. Last year, Merck KGaA (Xetra:MRK) returned rights to IMO-2055...
BioCentury | Jan 30, 2012
Clinical News

IMO-2055: Additional Phase Ib data

...evaluable patients with advanced NSCLC who failed >=1 prior course of chemotherapy showed that subcutaneous IMO-2055...
...control rate (DCR) of 79%. Median PFS and OS were 5.6 and 16 months, respectively. IMO-2055...
...U.S., while Roche markets it elsewhere. Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Cambridge, Mass. Product: IMO-2055 , EMD 1201081...
BioCentury | Dec 5, 2011
Company News

Idera, Merck KGaA deal

...Idera regained rights to cancer product IMO-2055 following the termination of a 2007 deal with Merck...
...2007 deal with Merck. In July, Idera said Merck would not conduct further development of IMO-2055...
...Phase II or Phase III trial and a regulatory submission for IMO-2055 in any country. IMO-2055...
BioCentury | Dec 1, 2011
Company News

Idera up as IMO-2055 deal ends

...NASDAQ:IDRA) gained $0.17 (15%) to $1.31 on Wednesday as it regained rights to cancer product IMO-2055...
...with Merck KGaA (Xetra:MRK). In July, Idera said Merck would not conduct further development of IMO-2055...
...agreed to reimburse about EUR 1.8 million ($2.4 million) of Merck's expenses for the trial. IMO-2055...
BioCentury | Oct 3, 2011
Finance

Few Cinderellas this time

...who are receiving standard therapy Idera Pharmaceuticals Inc. (NASDAQ:IDRA)/Merck KGaA (Xetra:MRK) Merck stops development of IMO-2055...
BioCentury | Jul 11, 2011
Finance

Highlights of weekly biotech stock moves

...to $1.90 last week after announcing partner Merck KGaA (Xetra:MRK) will not continue to develop IMO-2055...
...neutropenia and electrolyte imbalances were reported in a Phase Ib trial. The study was evaluating IMO-2055...
Items per page:
1 - 10 of 57